| scholarly article | Q13442814 |
| P2093 | author name string | Y. Qian | |
| S. M. Sebti | |||
| A. D. Hamilton | |||
| E. C. Lerner | |||
| P2860 | cites work | Cancer Research | Q326097 |
| Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit | Q24301326 | ||
| Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases | Q28116052 | ||
| All ras proteins are polyisoprenylated but only some are palmitoylated | Q28270312 | ||
| Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice | Q28369454 | ||
| ras genes | Q29547799 | ||
| Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors | Q33743285 | ||
| Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides | Q34219356 | ||
| p21ras is modified by a farnesyl isoprenoid | Q34315409 | ||
| Biochemistry of protein prenylation | Q35654997 | ||
| Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae | Q36690625 | ||
| Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein | Q36816986 | ||
| Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity | Q37108753 | ||
| A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity | Q37532652 | ||
| Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation | Q37739922 | ||
| Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic | Q40745426 | ||
| Activators and effectors of ras p21 proteins | Q40757563 | ||
| MAP kinase kinase kinase, MAP kinase kinase and MAP kinase | Q40757575 | ||
| Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes | Q41271748 | ||
| Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells | Q41546925 | ||
| Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor | Q41546932 | ||
| Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. | Q54177555 | ||
| Signal transduction. How receptors turn Ras on. | Q55066288 | ||
| A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing | Q72411082 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | alkyl and aryl transferases | Q78045053 |
| P304 | page(s) | 26770-26773 | |
| P577 | publication date | 1995-11-01 | |
| 1995-11-10 | |||
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor | |
| Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor | |||
| P478 | volume | 270 |
| Q43559496 | 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells. involvement of geranylgeranylation of small G protein Rap1. |
| Q47761479 | A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells |
| Q40308550 | A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity |
| Q33812895 | A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting |
| Q43556623 | Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors |
| Q53853231 | Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development. |
| Q44282764 | Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease |
| Q34940620 | Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. |
| Q34311585 | Blocking oncogenic Ras signaling for cancer therapy |
| Q38546927 | Chemistry and biology of the compounds that modulate cell migration |
| Q37891171 | Cholesterol and chronic hepatitis C virus infection. |
| Q28567838 | Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells |
| Q46698294 | Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells |
| Q37114315 | Control of the innate immune response by the mevalonate pathway. |
| Q43832782 | Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase. |
| Q42800460 | Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo |
| Q49721819 | Direct inhibition of RAS: Quest for the Holy Grail? |
| Q37304601 | Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation |
| Q73469099 | Disrupting the geranylgeranylation at the C-termini of the shrimp Ras by depriving guanine nucleotide binding at the N-terminal |
| Q42829042 | Disrupting the transforming activity of shrimp ras(Q(61)K) by deleting the CAAX box at the C-terminus |
| Q34792600 | Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation |
| Q39746249 | Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis |
| Q40966427 | Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells |
| Q42808715 | Effects of prenyl pyrophosphates on the binding of S-Ras proteins with KSR. |
| Q33832634 | Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway |
| Q41588527 | Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth |
| Q34293555 | Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies |
| Q34090957 | Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues |
| Q41489707 | Farnesyltransferase as a target for anticancer drug design |
| Q41094489 | Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? |
| Q44588836 | Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf |
| Q47830137 | Farnesyltransferase inhibitors versus Ras inhibitors. |
| Q42822828 | GTPase stimulation in shrimp Ras(Q(61)K) with geranylgeranyl pyrophosphate but not mammalian GAP. |
| Q55476334 | Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. |
| Q28477527 | Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I |
| Q28506550 | Implication of geranylgeranyltransferase I in synapse formation |
| Q34680671 | In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells |
| Q37033090 | Inactivation of rho GTPases by statins attenuates anthrax lethal toxin activity |
| Q33861555 | Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited |
| Q41027322 | Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth |
| Q41615096 | Inhibition of Ras prenylation: a novel approach to cancer chemotherapy |
| Q53404937 | Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors. |
| Q43737962 | Inhibition of geranylgeranylation blocks agonist-induced actin reorganization in human airway smooth muscle cells |
| Q28567450 | Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells |
| Q34047193 | Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics |
| Q33317126 | Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds |
| Q41515936 | Inhibitors of the Ras signal transduction pathway as potential antitumour agents |
| Q77596575 | Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target |
| Q40573637 | Isoprenoid-mediated control of SMAD3 expression in a cultured model of cystic fibrosis epithelial cells |
| Q35192456 | K-ras is an essential gene in the mouse with partial functional overlap with N-ras |
| Q24626407 | Localization and activity of the SNARE Ykt6 determined by its regulatory domain and palmitoylation |
| Q73783906 | Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway |
| Q34661270 | Maximizing mouse cancer models |
| Q33669995 | Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors |
| Q40744609 | Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells |
| Q56482817 | Molecular Recognition in Biomimetic Receptors |
| Q35790783 | Novel targeted agents in the treatment of lung cancer |
| Q53599892 | Palladium(II)-catalyzed ortho-C-H arylation/alkylation of N-benzoyl α-amino ester derivatives. |
| Q40623241 | Pharmacological modulation of fatty acid desaturation and of cholesterol biosynthesis in THP‐1 cells |
| Q42807654 | Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation |
| Q26863474 | Preclinical Murine Models for Lung Cancer: Clinical Trial Applications |
| Q41722127 | Prenylation of Ras GTPase superfamily proteins and their function in immunobiology. |
| Q38296605 | Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections |
| Q37981563 | Protein farnesylation and disease |
| Q27973925 | Protein farnesyltransferase and protein prenylation in Plasmodium falciparum |
| Q28277579 | Protein prenyltransferases |
| Q41271748 | Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes |
| Q74003428 | Ras regulation of radioresistance in cell culture |
| Q40586194 | Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway |
| Q37640365 | Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells |
| Q42799714 | RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. |
| Q42830713 | Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics |
| Q40872114 | Signal transduction pathways and their relevance in human astrocytomas |
| Q35575152 | Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma |
| Q40144861 | Small-molecule inhibitors of protein geranylgeranyltransferase type I. |
| Q112287776 | Statin-mediated disruption of Rho GTPase prenylation and activity inhibits respiratory syncytial virus infection |
| Q27930129 | Substrate specificity determinants in the farnesyltransferase beta-subunit |
| Q44529443 | Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors |
| Q42805583 | Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors |
| Q90681757 | Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo |
| Q34421358 | The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. |
| Q41085706 | The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner |
| Q77343239 | The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas |
| Q28238833 | The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors |
| Q35186888 | Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia |
| Q73308055 | Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells |
| Q33781631 | p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. |
Search more.